NCT00076401终止2 期
Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 27
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have chronic lymphocytic leukemia (CLL) that has come back after treatment or that has stopped responding to treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 18 years old
- •Refractory or relapsed CLL
- •ECOG performance status score of 0, 1, or 2
- •Each patient must sign a study-specific informed consent form
排除标准
- •Laboratory values of:
- •Platelet count <30,000/uL
- •AST or ALT >2 x the upper limit of normal (ULN)
- •Total bilirubin >2 x ULN
- •Creatinine >2.0 mg/dL
- •Chemotherapy, radiation therapy, immunotherapy, systemic corticosteroids, or systemic biologic anticancer therapy within 21 days before beginning study treatment
- •Women who are pregnant or lactating
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT00100711Pharmacyclics LLC.27
已完成
2 期
Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaLymphomaNCT00086034Pharmacyclics LLC.35
终止
2 期
Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)Lung CancerNCT00373204Pharmacyclics LLC.50
已完成
2 期
A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT00096837Pharmacyclics LLC.25
已完成
1 期
Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaSmall Lymphocytic LymphomaLymphomaLeukemiaChronic Lymphocytic LeukemiaNCT00290004Pharmacyclics LLC.35